$0.00
0.00%
Nasdaq, Sep 16, 04:00 pm EDT.
ISIN
US9282511073
Symbol
VRPX

Virpax Pharmaceuticals Inc Stock price

$0.01
+0.01 11,000.00% 1M
+0.01 3,600.00% 6M
+0.00 0.00% YTD
+0.00 0.00% 1Y
-192.36 99.99% 3Y
-1,434.99 100.00% 5Y
-2,499.99 100.00% 10Y
-2,499.99 100.00% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
+0.01 11,000.00%
ISIN
US9282511073
Symbol
VRPX
Industry

Is Virpax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$0.0
Enterprise Value
$-1.5m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.0
Financial Health
Equity Ratio
-58.7%
Return on Equity
1,320.6%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
1.8%
Employees
2
Rev per Employee
$0.0

Virpax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Virpax Pharmaceuticals Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Virpax Pharmaceuticals Inc forecast:

Hold
50%
Sell
50%

Financial data from Virpax Pharmaceuticals Inc

Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.26 6.26
41% 41%
-
- Research and Development Expense 5.82 5.82
14% 14%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
23% 23%
-
Net Profit -12 -12
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Virpax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.

Head office United States
CEO Mr. Dhaliwal
Employees 2
Founded 2016
Website virpaxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today